Diclofenamide (or dichlorphenamide) is a sulfonamide and a carbonic anhydrase
inhibitor of the meta-disulfamoylbenzene class.
Physician reviewed dichlorphenamide patient information - includes
dichlorphenamide description, dosage and directions.
dichlorphenamide | C6H6Cl2N2O4S2 | CID 3038 - structure, chemical names,
physical and chemical properties, classification, patents, literature, biological ...
Medscape - Periodic paralysis indication dosing for Keveyis (dichlorphenamide),
frequency-based adverse effects, comprehensive interactions, ...
Dec 1, 2015 ... Dichlorphenamide is used to treat inherited muscle disorders, such as primary
hyperkalemic periodic paralysis, primary hypokalemic periodic ...
Find patient medical information for dichlorphenamide oral on WebMD including
its uses, side effects and safety, interactions, pictures, warnings and user ...
Jun 13, 2005 ... 4,5-dichloro-m-benzenedisulfonamide. 4,5-DICHLOROBENZENE-1,3-
disulfonamide. Dichlofenamide. Dichlorophenamide. Dichlorphenamide.
KEVEYISTM (dichlorphenamide) tablets, for oral use. Initial U.S. Approval: ...
Hypersensitivity to dichlorphenamide or other sulfonamides (4). • Concomitant
Oct 14, 2011 ... A phase 3 trial of the drug dichlorphenamide in hyperkalemic and hypokalemic
periodic paralysis is open at several U.S. and European centers.
Apr 11, 2016 ... Dichlorphenamide (Keveyis – Taro), an oral carbonic anhydrase inhibitor, has
been approved by the FDA for treatment of primary hypokalemic ...